microRNA‑572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis

Abstract

Renal cell carcinoma (RCC) is the third most common urological malignancy in the USA and represents 2‑3% of all adult malignancies. Furthermore, the incidence of RCC has been progressively increasing over recent years. Although the morbidity of treatment has decreased with the use of multidisciplinary synthetic therapy, the prognosis of terminal cancer remains poor, with a 5‑year survival rate of 5‑10%. MicroRNAs (miRs) have been correlated with the regulation of 30‑60% of the protein-coding genes and act as oncogenes or anti‑oncogenes in RCC. Considering this research, miRNAs are likely to be the biomarkers for tumor diagnosis, prognosis and the targets for RCC management. In the present study, 42 formalin‑fixed paraffin‑embedded RCC samples were used. The expression of miR‑572 and the role of miR‑572 in RCC cell proliferation, migration and apoptosis was determined by performing reverse transcription‑quantitative polymerase chain reaction analysis, wound scratch assays, cell proliferation assays, Transwell assays and flow cytometry assays, respectively. Further experiments were conducted to clarify the correlation between miR‑572 expression and clinicopathological variables or overall survival. Furthermore, the expression levels of miR‑572 were evaluated for the prognosis value of patients with RCC. Upregulation of miR‑572 was observed in RCC tissues and RCC cell lines. miR‑572 promoted 786‑O and ACHN cell proliferation and mobility and inhibited early apoptosis. In Cox proportional hazard regression analyses, results of the univariate and multivariate analysis indicated that the patients with low miR‑572 expression had a significantly longer overall survival compared with the patients with high miR‑572 expression (univariate analysis, P=0.037; multivariate analysis, P=0.034). Results of the Kaplan‑Meier survival curves revealed that the patients with downregulated miR‑572 have a significantly longer overall survival compared with the patients with highly expressed miR‑572 (P=0.019). To conclude, the results of the present study suggest that tumor oncogene miR‑572 is a potential biomarker for the diagnosis, treatment and prognosis for RCC.

<p>miR-106b promotes proliferation and invasion by targeting Capicua through MAPK signaling in renal carcinoma cancer</p>

“…And miR-106b levels were not correlated with sex, age, whilst noticeable difference was found between miR-106 expression and tumor stage, pathology grade and lymph node metastasis. These outcomes suggested that miR-106b may serve as a potential independent prognostic marker for RCC, which functioned similarly to miR-21 and miR-223, 43 miR-154-5p, 44 miR-572 45 and so on.…”

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

“…As for miR-193a-3p, it was shown to target the tumor suppressor phosphatase and tensin homolog (PTEN) and mediate the PI3K/Akt pathway, thereby promoting RCC cell growth and progression ( Liu L. et al, 2017 ; Pan Y. et al, 2018 ). miR-572 likewise represents an oncomir in RCC pathogenesis by enhancing proliferation and invasion and inhibiting tumor cell apoptosis by suppressing NF2/Hippo signaling ( Guan et al, 2018 ; Pan et al, 2018a ). On the other hand, miR-28-5p ( Wang et al, 2016 ) and miR-362 ( Zou et al, 2016 ; Zhu et al, 2020 ) were suggested as tumor-suppressive miRNAs in RCC, although the miR-362 serum levels were increased in the study by Wang et al (2015) .…”

Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples

“…Interestingly, we also observed the significant downregulation of several miRNAs. Among them, some are already described in literature such as miRNA-572, prognosis biomarker for renal cell carcinoma and sclerosis [44,45], or miRNA-769, included in a miRNA panel for discrimination between Mycobacterium tuberculosis infected and healthy individuals [46].…”